Avita Medical Ltd (RCEL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Avita Medical Ltd stock (RCEL) is currently trading at $3.99. Avita Medical Ltd PS ratio (Price-to-Sales) is 1.69. Analyst consensus price target for RCEL is $8.38. WallStSmart rates RCEL as Sell.
- RCEL PE ratio analysis and historical PE chart
- RCEL PS ratio (Price-to-Sales) history and trend
- RCEL intrinsic value — DCF, Graham Number, EPV models
- RCEL stock price prediction 2025 2026 2027 2028 2029 2030
- RCEL fair value vs current price
- RCEL insider transactions and insider buying
- Is RCEL undervalued or overvalued?
- Avita Medical Ltd financial analysis — revenue, earnings, cash flow
- RCEL Piotroski F-Score and Altman Z-Score
- RCEL analyst price target and Smart Rating
Avita Medical
📊 No data available
Try selecting a different time range
Smart Analysis
Avita Medical Ltd (RCEL) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Avita Medical Ltd (RCEL) Key Strengths (1)
Paying $1.69 for every $1 of annual revenue
Supporting Valuation Data
Avita Medical Ltd (RCEL) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -4.30%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 11.8x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Avita Medical Ltd (RCEL) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales. Valuation metrics including Price/Sales (1.69) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Book (11.77) suggest expensive pricing. Growth concerns include Revenue Growth at -4.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -1746.00%, Operating Margin at -59.10%, Profit Margin at -67.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1746.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -4.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RCEL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RCEL's Price-to-Sales ratio of 1.69x sits near its historical average of 1.94x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 21% below its historical high of 2.15x set in Mar 2026, and 0% above its historical low of 1.69x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~2.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Avita Medical Ltd (RCEL) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Avita Medical Ltd is in a turnaround phase, with management focused on restoring profitability. Revenue reached 72M with 4% decline year-over-year. The company is currently unprofitable, posting a -67.8% profit margin.
Key Findings
Debt-to-equity ratio of -0.13 indicates a conservative balance sheet with 10M in cash.
The company is unprofitable with a -67.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.81, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Avita Medical Ltd.
Bottom Line
Avita Medical Ltd is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(6 last 3 months)
| Insider | Type | Shares |
|---|---|---|
O'TOOLE, DAVID D CFO | Buy | +1,800 |
| Insider | Type | Shares |
|---|---|---|
O'TOOLE, DAVID D CFO | Buy | +3,000 |
Data sourced from SEC Form 4 filings
Last updated: 12:56:17 PM
About Avita Medical Ltd(RCEL)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
AVITA Medical Inc. is a commercial stage regenerative tissue company in the United States, Australia, and the United Kingdom. The company is headquartered in Valencia, California.